G1 Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
G1 Therapeutics has a total shareholder equity of $35.4M and total debt of $51.6M, which brings its debt-to-equity ratio to 145.7%. Its total assets and total liabilities are $121.5M and $86.2M respectively.
Key information
145.7%
Debt to equity ratio
US$51.56m
Debt
Interest coverage ratio | n/a |
Cash | US$82.16m |
Equity | US$35.39m |
Total liabilities | US$86.15m |
Total assets | US$121.54m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: G1H's short term assets ($114.9M) exceed its short term liabilities ($29.7M).
Long Term Liabilities: G1H's short term assets ($114.9M) exceed its long term liabilities ($56.4M).
Debt to Equity History and Analysis
Debt Level: G1H has more cash than its total debt.
Reducing Debt: G1H's debt to equity ratio has increased from 0% to 145.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G1H has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if G1H has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.